1.00 (-%)
As of Nov 20, 2024
Source:
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company developing pelareorep, a safe and well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments.
Country | Canada |
Headquarters | calgary |
Phone Number | 4036707380 |
Industry | manufacturing |
CEO | Dr. Matthew Coffey |
Website | www.oncolyticsbiotech.com |